EntryPoint Capital LLC Decreases Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

EntryPoint Capital LLC trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 48.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 16,337 shares of the company’s stock after selling 15,296 shares during the quarter. EntryPoint Capital LLC’s holdings in Guardant Health were worth $499,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after acquiring an additional 350,606 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Eventide Asset Management LLC boosted its stake in shares of Guardant Health by 2.0% during the 3rd quarter. Eventide Asset Management LLC now owns 3,837,300 shares of the company’s stock valued at $88,028,000 after purchasing an additional 76,762 shares in the last quarter. Geode Capital Management LLC raised its stake in Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after buying an additional 29,686 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in Guardant Health by 19.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock worth $44,732,000 after buying an additional 238,037 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GH shares. The Goldman Sachs Group upped their target price on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Guggenheim restated a “buy” rating and set a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Canaccord Genuity Group increased their price target on shares of Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. Barclays assumed coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price objective on the stock. Finally, Piper Sandler raised their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health currently has an average rating of “Buy” and an average target price of $48.40.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $46.46 on Wednesday. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of -13.05 and a beta of 1.50. The business has a 50-day simple moving average of $44.20 and a two-hundred day simple moving average of $33.95. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.